Please find below the agenda for Life Sciences Patent Network North America. The agenda will continue to evolve over the coming weeks so please check back regularly for updates.
Thursday, June 1, 2017
8:00 AM - 8:30 AMREGISTRATION
Welcome coffee and networking
 
8:30 AM - 8:40 AMCHAIRMAN'S OPENING ADDRESS
Peter Scott
Group Publisher
Life Sciences IP Review
 
8:40 AM - 9:00 AMGLOBAL PATENT PROTECTION OUTLOOK
Global Patent Enforceability: Status and Outlook
  • Recent case law round-up
  • Compare US PTAB proceedings with European oppositions
  • Review of pharma and biotech cases at the PTAB
  • Life Sciences cases before the UPC and challenges for the new court
Anita Varma, Intellectual Property Partner, White & Case
Charles Larsen, Intellectual Property Partner, White & Case
 
9:00 AM - 9:45 AMUS PATENT ENFORCEMENT OUTLOOK
The Future US Patent Landscape: What level of patent reform is likely under the new administration?
  • The likely direction of the US Supreme Court: Will there be a reversal of the slide away from a property rights oriented American patent system?
  • How might patent harmonization look in light of a Trans-Pacific Partnership volte-face?
  • A US Pharma Perspective on Global Patent Eligibility – The Vision – and the Challenge
Moderator: 
Eldora Ellison, Director, Sterne Kessler Goldstein & Fox
 
Panellists:
Scott Alban, Vice President, Global Intellectual Property, AstraZeneca
Barbara Fiacco, Second Vice President, American Intellectual Property Law Association
Kimya Harris, Senior Director, Intellectual Property, R&D, ImmunoGen
 
9:45 AM - 10:05 AMPOST-GRANT PROCEEDINGS
Recent developments in Post-Grant Proceedings and their impact on life sciences companies
 
Eldora Ellison, Director, Sterne Kessler Goldstein & Fox
 
10:05 AM - 10:30 AMEUROPE FOCUS

Brexit and the future European patent landscape

  • Where are we at present and to where are we carving a path?
  • ​Thoughts on the Unified Patent Court and the Unitary Patent system:  What will be the practical impact of Brexit?     
  • Pros and cons of EMA v a new UK regulator
 
Nicola Dagg, Global Head of IP, Allen & Overy
 
10:30 AM - 10:45 AMASIA MARKET INSIGHT

Pharmaceutical patent litigation in China

Dr S. Sam Li, Senior Partner, Wan Hui Da

 
10:45 AM - 11:15 AMMORNING COFFEE AND NETWORKING  
11:15 AM - 12:00 PMBIOLOGICS PANEL DISCUSSION
CHAMPIONING CUTTING EDGE INNOVATION WITH ROBUST PATENT PROTECTION
Who's setting the agenda on biologics?
  • Ensuring effective protection for antibodies
  • Is it advisable to use trade secrets protection rather than patenting?
  • Do biosimilar applicants have to join in the patent dance?
Moderator: 
Barbara Fiacco, Second Vice President, American Intellectual Property Law Association
 
Panellists: 
Brendan O'Malley, Partner, Fitzpatrick Cella Harper & Scinto
Larry Coury, Senior Director of Dispute Resolution, Regeneron
Ahmed Mousa, VP Licensing, IP & Legal Affairs, Pieris Pharmaceuticals 
Paul Inman, Partner, Gowling WLG
 
12:00 PM - 12:15 PMCRISPR SECTION FOCUS - MODERATED BY FRITS GERRITZEN

KEY CONFERENCE ADDRESS

Principles for Disseminating Scientific Innovation

  • Licensing CRISPR IP
  • The CRISPR based 'inclusive innovation' model 

Issi Rozen, Chief Business Officer, The Broad Institute of MIT and Harvard

 
12:15 PM - 12:45 PMKEYNOTE PANEL DISCUSSION
The rise and rise of CRISPR Technology
  • The current state of play: Patent battles in the US and Europe
  • How licensing can best serve the public
  • The practical and legal challenges of gene editing
  • What's the licensing outlook and where are the opportunities?
Moderator: 
Frits Gerritzen, Partner, Allen & Overy

Panellists: 
Issi Rozen, Chief Business Officer, The Broad Institute of MIT and Harvard
Catherine Coombes, Senior Patent Attorney, HGF
Jared Cohen, Senior Director, Patent Counsel, Alexion Pharmaceuticals
Larry Coury, Senior Director of Dispute Resolution, Regeneron
 
12:45 PM - 1:45 PMLUNCH BREAK
Lunch and Networking in the Hamilton Room
 
1:45 PM - 1:50 PMROUNDTABLE DISCUSSION GROUPS
Taking part in these discussions offers delegates and speakers the opportunity to focus on topics of specific interest, within a small group. 35 minutes is set aside for each rotation – and delegates may choose two discussion tables. The roundtable discussion groups give delegates even more opportunity to share knowledge and opinion, and ends with a moderator round-up of key findings, providing delegates with an insight into all eight topics.
 
SESSION 1 - PLEASE CHOOSE YOUR FIRST TABLE FROM THE FOLLOWING:
 
1:50 PM - 2:20 PMTABLE THREE -
Infringement of Method of Use patents
Brian Slater, Partner, Kramer Levin
ROUNDTABLE
1:50 PM - 2:20 PMTABLE TWO -
Navigating the CRISPR patent landscape and licensing landscape
Catherine Coombes, Senior Patent Attorney, HGF
ROUNDTABLE
1:50 PM - 2:20 PMTABLE FOUR -
Patent prosecution, patent linkage and data protection in China
Wenping Chen, Partner, King & Wood Mallesons
ROUNDTABLE
1:50 PM - 2:20 PMTABLE SIX -
Licensing and joint ownership of IP: Who has control?
Deirdre Cunnane, SVP, General Counsel, Catabasis Pharmaceuticals
ROUNDTABLE
1:50 PM - 2:20 PMTABLE EIGHT -

Strategies in second medical use cases
Catherine Eckenswiller, Legal Counsel, IP and Contracts, VBI Vaccines

ROUNDTABLE
1:50 PM - 2:20 PMTABLE ONE -
Pharmaceutical Patent Litigation in China
Sam Li, Senior Partner, Wan Hui Da
ROUNDTABLE
1:50 PM - 2:20 PMTABLE FIVE -
Thoughts on the Unified Patent Court and the Unitary Patent System: What will be the practical impact of Brexit?
Zoe Butler, Partner, Powell Gilbert
ROUNDTABLE
1:50 PM - 2:20 PMTABLE SEVEN -
Life Sciences Patents Open Table
Solving in-house counsel challenges
Nicola Dagg, Global Head of IP, Allen & Overy 
Frits Gerritzen, Partner, Allen & Overy
ROUNDTABLE
2:20 PM - 2:25 PMSESSION 2 - PLEASE CHOOSE YOUR SECOND TABLE FROM THE FOLLOWING:   
2:25 PM - 3:00 PMTABLE TWO -
Navigating the CRISPR patent landscape and licensing landscape
Catherine Coombes, Senior Patent Attorney, HGF
ROUNDTABLE
2:25 PM - 3:00 PMTABLE FIVE -
Thoughts on the Unified Patent Court and the Unitary Patent System: What will be the practical impact of Brexit?
Zoe Butler, Partner, Powell Gilbert
ROUNDTABLE
2:25 PM - 3:00 PMTABLE SIX -
Licensing and joint ownership of IP: Who has control?
Deirdre Cunnane, SVP, General Counsel, Catabasis Pharmaceuticals
ROUNDTABLE
2:25 PM - 3:00 PMTABLE ONE -
Pharmaceutical Patent Litigation in China
Sam Li, Senior Partner, Wan Hui Da
ROUNDTABLE
2:25 PM - 3:00 PMTABLE SEVEN -
Life Sciences Patents Open Table
Solving in-house counsel challenges
Nicola Dagg, Global Head of IP, Allen & Overy 
Frits Gerritzen, Partner, Allen & Overy
ROUNDTABLE
2:25 PM - 3:00 PMTABLE EIGHT -

Strategies in second medical use cases
Catherine Eckenswiller, Legal Counsel, IP and Contracts, VBI Vaccines

ROUNDTABLE
2:25 PM - 3:00 PMTABLE FOUR -
Patent prosecution, patent linkage and data protection in China
Wenping Chen, Partner, King & Wood Mallesons
ROUNDTABLE
2:25 PM - 3:00 PMTABLE THREE -
Infringement of Method of Use patents
Brian Slater, Partner, Kramer Levin
ROUNDTABLE
3:00 PM - 3:15 PMROUND UP
Discussion group round-up: Key findings and points of note
 
3:15 PM - 3:40 PMBREAK
Afternoon Tea and Networking in the Hamilton Room
 
3:40 PM - 4:10 PMSECOND MEDICAL USE

Addressing second medical use infringement

  • Analysis of recent ket cases and overview of varying jurisdictions
  • Why we need global harmonization of patentability
  • What must generic manufacturers do prior to product launch, where a second medical use patent is in force?
  • What practical steps must a second medical use patent owner take when infringement is suspected?

Moderator: 
White & Case

Panellists: 
Lydia McNally, VP, Patent Head,  Oncology and US Patent Site Head, Novartis
Catherine Eckenswiller, Legal Counsel, IP and Contracts, VBI Vaccines
John Prince, Senior Patent Attorney, NIBR Novartis

 
4:10 PM - 4:30 PMIP PORTFOLIO MANAGEMENT

Canadian IP Portfolio Management within the Global Context

  • Best practices in view of the evolving linkage regime, supplementary protection and market access issues
  • Internal business alignment: Matching commercial expectations with your current patent status
  • Licensing considerations and opportunities
Daphne Lainson, Partner, Smart & Biggar
 
4:30 PM - 5:00 PMPANEL DISCUSSION
IP Portfolio Management: Addressing the conflicting pressures to publish and publicize, with the desire to maintain IP rights
 
Moderator: 
Daphne Lainson, Partner, Smart & Biggar
 
Panellists: 
Ahmed Mousa, VP Licensing, IP & Legal Affiars, Pieris Pharmaceuticals
Kimya Harris, Senior Director, Intellectual Property, R&D, ImmunoGen
Jennifer Loebach, Director, Intellectual Property, Blueprint Medicines
 
5:00 PM - 6:00 PMCLOSING DRINKS RECEPTION
Join us for Drinks and Canapes in the Hamilton Room!